Welcome to Heron Therapeutics

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company's lead product, Sustol™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its Sustol New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration in mid-2014.

Recent News

March 31, 2014

Heron Therapeutics Initiates Phase 3 Label Expansion Study of SUSTOL™

March 5, 2014

Heron Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Corporate Progress

January 27, 2014

Heron Therapeutics Provides Update on Sustol Resubmission

More News